Patents by Inventor Agnes Eva Hamburger

Agnes Eva Hamburger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11072640
    Abstract: The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: July 27, 2021
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Publication number: 20210079051
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 18, 2021
    Applicant: AMGEN INC.
    Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. ZHENG, Agnes Eva HAMBURGER, Murielle M. VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Marissa MOCK, Kenneth William WALKER
  • Publication number: 20210017261
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: July 1, 2020
    Publication date: January 21, 2021
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Patent number: 10894814
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: January 19, 2021
    Assignee: AMGEN INC.
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle M. Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Marissa Mock, Kenneth William Walker
  • Patent number: 10793631
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: October 6, 2020
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Patent number: 10738110
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 11, 2020
    Assignee: AMGEN INC.
    Inventors: Neeraj Jagdish Agrawal, Kevin Graham, Agnes Eva Hamburger, Christopher Mohr, Derek E. Piper, Kenneth William Walker, Zhulun Wang, Cen Xu
  • Publication number: 20200172614
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Application
    Filed: September 16, 2019
    Publication date: June 4, 2020
    Applicant: AMGEN INC.
    Inventors: Cen XU, Agnes Eva HAMBURGER
  • Patent number: 10472417
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: November 12, 2019
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Publication number: 20190315822
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: May 17, 2019
    Publication date: October 17, 2019
    Applicant: Amgen Inc.
    Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. SHENG, Agnes Eva HAMBURGER, Murielle M. VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Kenneth W. WALKER, Bryan LEMON
  • Publication number: 20190218279
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 18, 2019
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Patent number: 10336798
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: July 2, 2019
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle M. Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Kenneth W. Walker, Bryan Lemon
  • Patent number: 10294298
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 21, 2019
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Publication number: 20190023757
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: June 1, 2018
    Publication date: January 24, 2019
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Publication number: 20180362645
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Application
    Filed: June 25, 2018
    Publication date: December 20, 2018
    Applicant: AMGEN INC.
    Inventors: Cen XU, Agnes Eva HAMBURGER
  • Patent number: 10053507
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 21, 2018
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • Patent number: 10011642
    Abstract: The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: July 3, 2018
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Publication number: 20180094055
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
    Type: Application
    Filed: October 18, 2017
    Publication date: April 5, 2018
    Applicant: AMGEN INC.
    Inventors: Cen XU, Agnes Eva HAMBURGER
  • Publication number: 20180079790
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: November 29, 2017
    Publication date: March 22, 2018
    Applicant: Amgen Inc.
    Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. SHENG, Agnes Eva HAMBURGER, Murielle M. VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Marissa MOCK, Kenneth William WALKER
  • Patent number: 9862752
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: January 9, 2018
    Assignee: Amgen Inc.
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Marissa Mock, Kenneth Walker
  • Patent number: 9822178
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: November 21, 2017
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger